GlobalData
GlobalData

Sarath.Chandra@globaldata.com

  • Home
  • Author: Sarath.Chandra@globaldata.com

North America to drive global small-scale LNG liquefaction capacity additions through 2027, says GlobalData

North America is expected to witness the highest small-scale LNG liquefaction capacity additions globally during 2023-2027, contributing about 32% of the total global small-scale LNG liquefaction capacity additions by 2027, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Small-Scale LNG Liquefaction Capacity and Capital Expenditure (CapEx) Forecast by Region, Key Countries, Companies […]
Read more

Amneal Parkinson’s drug IPX203 needs to compete with novel subcutaneous levodopa delivery systems post FDA CRL, says GlobalData

Following the news that Amneal Pharmaceuticals received a complete response letter (CRL) from the FDA, concerning its new drug application for IPX203 (carbidopa/levodopa) as a treatment for Parkinson’s disease (PD); Christie Wong, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “Although levodopa has been the gold standard for patients with […]
Read more

Banking and payments industry takes center stage in AI discussions during Q2 2023, reveals GlobalData

Artificial intelligence (AI) continues to influence the way we live and work, generating a lot of discussions across different industries. The banking and payments industry had the highest discussions about AI after technology during the second quarter (Q2) of 2023, reveals the Company Filings Analytics Database of GlobalData, a leading data and analytics company. Misa […]
Read more

Bad clinical practices overshadow BioXcel positive results for Igalmi in Alzheimer’s agitation, says GlobalData

Following the news that BioXcel Therapeutics announced positive top-line results from TRANQUILITY II (NCT05271552), a Phase III study of Igalmi (dexmedetomidine sublingual film) for the acute treatment of agitation episodes associated with Alzheimer’s disease (AD); Philippa Salter, Senior Neurology Analyst at GlobalData, offers her view: “Although the clinical trial met its primary endpoint for the […]
Read more

Microsoft, Salesforce generative AI investments drive innovation in low-code platforms, reveals GlobalData report

The digital transformation era has brought forth the need for accelerated app development and intelligent automation, prompting innovative enterprises to investigate how they can utilize emerging technologies in their businesses. Under this backdrop, Microsoft and Salesforce have been named leaders in the low-code space for their integration of generative AI, according to GlobalData, a leading […]
Read more

India economy set for robust growth in 2023, driven by domestic consumption and infrastructure boost, says GlobalData

Amidst a gloomy global economic scenario, India emerges as a ray of hope and is positioned to achieve the highest GDP growth rate among major economies in 2023. The growth will be driven by robust private consumption and investment, supported by government efforts to enhance infrastructure, logistics, and the overall business climate. However, a decline […]
Read more

Synthetic data startups redefining AI landscape to unlock new frontiers across industries, says GlobalData

Synthetic data startups are spearheading a revolution in artificial intelligence (AI) by redefining the landscape of data generation. With substantial venture capital investments and a clear sense of direction, these startups are transforming industries, overcoming data limitations, and propelling AI innovation to new heights, according to GlobalData, a leading data and analytics company. Kiran Raj, […]
Read more

Zolbetuximab niche patient target in gastric cancer will limit its potential in Japan, says GlobalData

Astellas Pharma recently filed new drug application (NDA) in Japan for zolbetuximab, a novel chimeric immunoglobulin G1 antibody highly specific for Claudin 18 isoform 2 (CLDN18.2) for the first-line treatment of gastric cancer patients. Following approval, the drug is expected to have limited potential in the first-line treatment setting, considering the clinical success of its […]
Read more

FDA approval for Pfizer Talzenna paves way for advanced treatment of gene-mutated metastatic prostate cancer, says GlobalData

Pfizer has received FDA approval for Talzenna, a combination therapy with Xtandi, as a treatment for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations. Talzenna becomes the first and only PARP inhibitor approved for use in combination with Xtandi, offering new hope for patients. Sales projections indicate significant growth potential, making […]
Read more

Unravel ESG 2.0 with GlobalData: Decoding decarbonisation and harnessing sustainable growth opportunities

As the landscape of environmental, social, and governance (ESG) considerations continues to evolve, it is essential for companies to stay ahead of the curve and adapt their strategies accordingly. Against this backdrop, GlobalData’s Thematic Intelligence team invites you to attend “ESG 2.0: Decoding Decarbonisation” webinar on Thursday, 29 June at 4pm BST/11am EST. During this […]
Read more

Intercept opportunity to market first-ever NASH therapy diminishes with negative FDA GDAC vote, says GlobalData

The FDA’s Gastrointestinal Drugs Advisory Committee (GDAC) has recently voted against Intercept Pharmaceutical’s new drug application (NDA) for obeticholic acid (OCA) 25 mg oral tablets as a treatment for pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH) on the basis that the benefits did not outweigh the risks. The move will significantly reduce the potential […]
Read more
1 … 100 101 102 103 104 … 209